Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule
- PMID: 3001934
- DOI: 10.1126/science.3001934
Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule
Abstract
Human T-lymphotropic virus type III (HTLV-III) or lymphadenopathy-associated virus (LAV) is tropic for human T cells with the helper-inducer phenotype, as defined by reactivity with monoclonal antibodies specific for the T4 molecule. Treatment of T4+ T cells with monoclonal antibodies to T4 antigen blocks HTLV-III/LAV binding, syncytia formation, and infectivity. Thus, it has been inferred that the T4 molecule itself is a virus receptor. In the present studies, the surfaces of T4+ T cells were labeled radioactively, and then the cells were exposed to virus. After the cells were lysed, HTLV-III/LAV antibodies were found to precipitate a surface protein with a molecular weight of 58,000 (58K). By blocking and absorption experiments, this 58K protein was identified as the T4 molecule. No cell-surface structures other than the T4 molecule were involved in the antibody-antigen complex formation. Two monoclonal antibodies, each reactive with a separate epitope of the T4 molecule, were tested for their binding capacities in the presence of HTLV-III/LAV. When HTLV-III/LAV was bound to T4+ T cells, the virus blocked the binding of one of the monoclonal antibodies, T4A (OKT4A), but not of the other, T4 (OKT4). When HTLV-III/LAV was internally radiolabeled and bound to T4+ T cells which were then lysed, a viral glycoprotein of 110K (gp110) coprecipitated with the T4 molecule. The binding of gp110 to the T4 molecule may thus be a major factor in HTLV-III/LAV tropism and may prove useful in developing therapeutic or preventive measures for the acquired immune deficiency syndrome.
Similar articles
-
Cellular tropism of the human retrovirus HTLV-III/LAV. I. Role of T cell activation and expression of the T4 antigen.J Immunol. 1985 Nov;135(5):3151-62. J Immunol. 1985. PMID: 2995487
-
In vitro infection of human monocytes with human T lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV).J Immunol. 1986 Jul 1;137(1):323-9. J Immunol. 1986. PMID: 3011909
-
T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.Nature. 1984 Dec 20-1985 Jan 2;312(5996):767-8. doi: 10.1038/312767a0. Nature. 1984. PMID: 6083454
-
Immunopathogenesis of the acquired immunodeficiency syndrome.Ann Intern Med. 1985 Nov;103(5):704-9. doi: 10.7326/0003-4819-103-5-704. Ann Intern Med. 1985. PMID: 2996403 Review.
-
Lymphadenopathy associated virus and its etiological role in AIDS.Princess Takamatsu Symp. 1984;15:319-31. Princess Takamatsu Symp. 1984. PMID: 6100650 Review.
Cited by
-
Characterization of a CXCR4 antagonist TIQ-15 with dual tropic HIV entry inhibition properties.PLoS Pathog. 2024 Aug 15;20(8):e1012448. doi: 10.1371/journal.ppat.1012448. eCollection 2024 Aug. PLoS Pathog. 2024. PMID: 39146384 Free PMC article.
-
Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines.NPJ Vaccines. 2024 Apr 6;9(1):74. doi: 10.1038/s41541-024-00862-8. NPJ Vaccines. 2024. PMID: 38582771 Free PMC article.
-
HIV-1 Infection of Long-Lived Hematopoietic Precursors In Vitro and In Vivo.Cells. 2022 Sep 23;11(19):2968. doi: 10.3390/cells11192968. Cells. 2022. PMID: 36230931 Free PMC article.
-
Contribution of the HIV-1 Envelope Glycoprotein to AIDS Pathogenesis and Clinical Progression.Biomedicines. 2022 Sep 2;10(9):2172. doi: 10.3390/biomedicines10092172. Biomedicines. 2022. PMID: 36140273 Free PMC article. Review.
-
HIV-1-Mediated Acceleration of Oncovirus-Related Non-AIDS-Defining Cancers.Biomedicines. 2022 Mar 25;10(4):768. doi: 10.3390/biomedicines10040768. Biomedicines. 2022. PMID: 35453518 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources